FI973323A - Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo - Google Patents

Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo Download PDF

Info

Publication number
FI973323A
FI973323A FI973323A FI973323A FI973323A FI 973323 A FI973323 A FI 973323A FI 973323 A FI973323 A FI 973323A FI 973323 A FI973323 A FI 973323A FI 973323 A FI973323 A FI 973323A
Authority
FI
Finland
Prior art keywords
exogens
expression
drug combination
vivo transfection
combination useful
Prior art date
Application number
FI973323A
Other languages
English (en)
Swedish (sv)
Other versions
FI973323A0 (fi
FI119176B (fi
Inventor
Jean-Francois Bach
Lucienne Chatenoud
Hedi Haddada
Martin Lee
Michel Perricaudet
Michelle Webb
Original Assignee
Rhone Poulenc Rorer Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa, Inst Nat Sante Rech Med filed Critical Rhone Poulenc Rorer Sa
Publication of FI973323A0 publication Critical patent/FI973323A0/fi
Publication of FI973323A publication Critical patent/FI973323A/fi
Application granted granted Critical
Publication of FI119176B publication Critical patent/FI119176B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI973323A 1995-02-14 1997-08-13 Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo FI119176B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9501662 1995-02-14
FR9501662A FR2730411B1 (fr) 1995-02-14 1995-02-14 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
FR9600218 1996-01-10
PCT/FR1996/000218 WO1996025177A1 (fr) 1995-02-14 1996-02-12 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes

Publications (3)

Publication Number Publication Date
FI973323A0 FI973323A0 (fi) 1997-08-13
FI973323A true FI973323A (fi) 1997-08-13
FI119176B FI119176B (fi) 2008-08-29

Family

ID=9476106

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973323A FI119176B (fi) 1995-02-14 1997-08-13 Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo

Country Status (23)

Country Link
US (2) US20030004091A1 (fi)
EP (1) EP0809516B1 (fi)
JP (1) JPH11500430A (fi)
KR (1) KR100402540B1 (fi)
AT (1) ATE204481T1 (fi)
AU (1) AU717218B2 (fi)
BR (1) BR9607310A (fi)
CA (1) CA2211039C (fi)
CZ (1) CZ258197A3 (fi)
DE (1) DE69614668T2 (fi)
DK (1) DK0809516T3 (fi)
ES (1) ES2163612T3 (fi)
FI (1) FI119176B (fi)
FR (1) FR2730411B1 (fi)
GR (1) GR3036438T3 (fi)
HU (1) HU222991B1 (fi)
IL (1) IL117116A0 (fi)
MX (1) MX9706017A (fi)
NO (1) NO320072B1 (fi)
PT (1) PT809516E (fi)
SK (1) SK282235B6 (fi)
WO (1) WO1996025177A1 (fi)
ZA (1) ZA961161B (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
EP0942747A1 (en) * 1996-08-26 1999-09-22 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
JP2001521743A (ja) 1997-10-30 2001-11-13 コーネル リサーチ ファウンデーション、インコーポレイティッド 組換えベクターに対する免疫応答の阻害方法
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU5470900A (en) * 1999-06-08 2000-12-28 Children's Hospital Of Philadelphia, The Methods for preventing formation of inhibitory antibodies in the setting of genetherapy
FR2799472B1 (fr) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
CA2876779A1 (en) 2000-05-12 2001-11-22 Genzyme Corporation Modulators of tnf-.alpha. signaling
EP1411770A4 (en) 2001-07-05 2006-05-10 Chiron Corp POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE
US7569217B2 (en) * 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
US20030139374A1 (en) * 2001-09-27 2003-07-24 Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. Combined methods for tumor vasculature coagulation and treatment
ES2363914T3 (es) * 2002-11-21 2011-08-19 Genzyme Corporation Utilización de un derivado de diamida para inhibir el rechazo crónico de un transplante.
US7217718B2 (en) * 2002-11-21 2007-05-15 Genzyme Corporation Induction of immune tolerance
WO2005076965A2 (en) * 2004-02-04 2005-08-25 The Trustees Of Columbia University In The City Of New York Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016065A1 (en) * 1992-12-31 1994-07-21 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells
WO1994016080A1 (en) * 1993-01-08 1994-07-21 Exemplar Corporation An in vitro/in vivo method for identifying anti-neoplastic drugs
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus

Also Published As

Publication number Publication date
KR19980702199A (ko) 1998-07-15
ATE204481T1 (de) 2001-09-15
FR2730411B1 (fr) 1997-03-28
CZ258197A3 (en) 1997-11-12
PT809516E (pt) 2002-02-28
ZA961161B (en) 1996-08-07
IL117116A0 (en) 1996-06-18
CA2211039A1 (fr) 1996-08-22
ES2163612T3 (es) 2002-02-01
DE69614668T2 (de) 2002-06-27
NO973724D0 (no) 1997-08-13
EP0809516A1 (fr) 1997-12-03
SK282235B6 (sk) 2001-12-03
HU222991B1 (hu) 2004-01-28
GR3036438T3 (en) 2001-11-30
JPH11500430A (ja) 1999-01-12
US20030004091A1 (en) 2003-01-02
MX9706017A (es) 1997-11-29
DE69614668D1 (de) 2001-09-27
BR9607310A (pt) 1997-11-25
AU717218B2 (en) 2000-03-23
NO320072B1 (no) 2005-10-17
CA2211039C (fr) 2011-12-06
FI973323A0 (fi) 1997-08-13
DK0809516T3 (da) 2001-12-17
HUP9800635A2 (hu) 1998-07-28
SK110897A3 (en) 1998-01-14
KR100402540B1 (ko) 2004-05-07
US20040265276A1 (en) 2004-12-30
NO973724L (no) 1997-08-13
WO1996025177A1 (fr) 1996-08-22
HUP9800635A3 (en) 2000-12-28
FI119176B (fi) 2008-08-29
AU4723896A (en) 1996-09-04
FR2730411A1 (fr) 1996-08-14
EP0809516B1 (fr) 2001-08-22

Similar Documents

Publication Publication Date Title
FI973323A0 (fi) Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo
BR9813202B1 (pt) complexo de administração de genes; processo de transdução de células com material genético estranho, composição útil para administração de material genético e uso de um complexo de administração de genes.
AU9676198A (en) Drug delivery and gene therapy delivery system
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
FI973467A (fi) DNA-molekyylejä, valmistus ja käyttö geeniterapiassa
PL325774A1 (en) Drug delivery system for two or more active substances
PT693924E (pt) Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
DK1037667T3 (da) Farmaceutiske hydrogelformuleringer, lægemiddelindgivelsesanordninger samt fremgangsmåder
ATE177657T1 (de) Intravaginales wirkstoffabgabesystem
AU2832297A (en) Morphogen treatment for chronic renal failure
ZA956264B (en) Surface expression of enzyme in gene directed prodrug therapy
DE69700983D1 (de) Ligandgerichtete enzyme-prodrug therapie
MX9700298A (es) Adenovirus que comprende un gen que codifica para una no sintasa.
NO20020604D0 (no) Fremgangsmåte for avlevering av terapeutiske midler ved bruk av en dekstrinlösning
Agrawal Antisense oligonucleotides as gene expression modulators
AR004227A1 (es) Uso de hialuronan en terapia genetica.
MX9706569A (es) Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica.
MX9803093A (es) Suministro de polipeptidos biologicamente activos.
IT239614Y1 (it) Siringa salva vita.

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 119176

Country of ref document: FI

MM Patent lapsed